Interleukin-1 beta (IL-1B), Interleukin-12 (IL-12), Interleukin-13 (IL-13), and Interleukin-4 (IL-4) (IL-1B, IL-12, IL-13, IL-4)

This entry represents a group of key signaling proteins—Interleukin-1 beta (IL-1β), Interleukin-12 (IL-12), Interleukin-13 (IL-13), and Interleukin-4 (IL-4)—that serve as critical mediators in the human immune system. IL-1β and IL-12 are primarily associated with pro-inflammatory and Th1-mediated responses, where IL-1β acts as a gatekeeper of innate inflammation and IL-12 drives the production of interferon-gamma (Dinarello, 2011; Gately et al., 1998). In contrast, IL-4 and IL-13 are the hallmark cytokines of the pro-allergic Th2 response, orchestrating IgE production, mucus hypersecretion, and eosinophil recruitment (Gandhi et al., 2016). Dysregulation of these cytokines is a central feature of various chronic inflammatory and allergic diseases, such as asthma, atopic dermatitis, and rheumatoid arthritis. Consequently, they are high-priority therapeutic targets; drugs like dupilumab (targeting the IL-4/IL-13 receptor) and canakinumab (targeting IL-1β) have been developed to modulate these pathways (Simpson et al., 2016). Monitoring biomarkers like IgE or C-reactive protein is often employed to track the efficacy of these cytokine-targeted interventions. These therapies aim to restore immune homeostasis by selectively inhibiting the overactive signaling pathways associated with specific disease phenotypes.

Other names

IL-1BIL-12IL-13IL-4Pro-inflammatory cytokinesPro-allergic cytokinesType 2 cytokinesTh1/Th2 cytokines

Monoclonal antibodies or receptor antagonists that neutralize the specific cytokine or block its cognate receptor to inhibit downstream signaling pathways such as JAK-STAT or NF-κB (Gandhi et al., 2016; Dinarello, 2011).